Page last updated: 2024-08-05 11:17:16
pyrazolopyridine
null
ChEBI ID: 46699
Members (22)
| Member | Definition | Role |
|---|---|---|
| 1-Benzyl-3-pyridin-3-yl-1H-pyrazole-4-carbaldehyde | 1-Benzyl-3-pyridin-3-yl-1H-pyrazole-4-carbaldehyde | |
| 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone | 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone | |
| 3-(4-morpholinyl)-4-(2-pyridinyl)-N-[3-(trifluoromethyl)phenyl]-1-pyrazolecarboxamide | 3-(4-morpholinyl)-4-(2-pyridinyl)-N-[3-(trifluoromethyl)phenyl]-1-pyrazolecarboxamide | |
| 3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4,6-bis(trifluoromethyl)pyrazolo[3,4-b]pyridine | 3-methyl-1-[2-(2H-tetrazol-5-yl)ethyl]-4,6-bis(trifluoromethyl)pyrazolo[3,4-b]pyridine | |
| 4-(4-chlorophenyl)-1-(6-fluoro-2-pyridinyl)-3-pyrazolamine | 4-(4-chlorophenyl)-1-(6-fluoro-2-pyridinyl)-3-pyrazolamine | |
| 4-[(1-ethyl-6-methyl-4-pyrazolo[3,4-b]pyridinyl)oxymethyl]benzonitrile | 4-[(1-ethyl-6-methyl-4-pyrazolo[3,4-b]pyridinyl)oxymethyl]benzonitrile | |
| 4-chloro-1-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester | 4-chloro-1-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester | |
| 4,6-bis(trifluoromethyl)-1,2-dihydropyrazolo[3,4-b]pyridin-3-one | 4,6-bis(trifluoromethyl)-1,2-dihydropyrazolo[3,4-b]pyridin-3-one | |
| 5-amino-1-(2-pyridinyl)-4-pyrazolecarboxylic acid ethyl ester | 5-amino-1-(2-pyridinyl)-4-pyrazolecarboxylic acid ethyl ester | |
| apixaban | A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases. | apixaban |
| bay 41-8543 | BAY-41-8543 | |
| bay 60-4552 | A member of the class of pyrazolopyridines that is 1H-pyrazolo[3,4-b]pyridine which is substituted by a 2-fluorobenzyl and 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl groups at positions 1 and 3, respectively. It is an active metabolite of riociguat and a soluble guanylate cyclase stimulator developed by Bayer for the treatment of erectile dysfunction and heart failure. | nelociguat |
| bay 63-2521 | A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension | riociguat |
| etazolate | A pyrazolopyridine that is 1H-pyrazolo[3,4-b]pyridine which is substituted at positions 1, 4, and 5 by ethyl, 2-isopropylidenehydrazino, and ethoxycarbonyl groups, respectively. A phosphodiesterase IV inhibitor with antidepressant and anxiolytic properties. | etazolate |
| ibudilast | Ibudilast | |
| ici 136,753 | 4-(butylamino)-1-ethyl-6-methyl-5-pyrazolo[3,4-b]pyridinecarboxylic acid ethyl ester | |
| jte 013 | A semicarbazide derivative that is semicarbazide in which the amino group at position 2 is replaced by a [1,3-dimethyl-4-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl]amino group and the amino group adjacent to the carbonyl is replaced by a (2,6-dichloropyridin-4-yl)amino group. It is a potent S1P2 antagonist (IC50 = 17.6 nM). | JTE-013 |
| N-[2-(1-tert-butyl-3,4,6-trimethyl-5-pyrazolo[3,4-b]pyridinyl)ethyl]carbamic acid ethyl ester | N-[2-(1-tert-butyl-3,4,6-trimethyl-5-pyrazolo[3,4-b]pyridinyl)ethyl]carbamic acid ethyl ester | |
| N-[2-(2,3,4-trimethoxyphenyl)ethyl]-2-pyrazolo[1,5-a]pyridinecarboxamide | N-[2-(2,3,4-trimethoxyphenyl)ethyl]-2-pyrazolo[1,5-a]pyridinecarboxamide | |
| pexacerfont | Pexacerfont | |
| repsox | 1,5-naphthyridine, 2-[3-(6-methyl-2-pyridinyl)-1h-pyrazol-4-yl]- | |
| vericiguat | A pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. | vericiguat |
Research
Studies (3,128)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 87 (2.78) | 18.7374 |
| 1990's | 35 (1.12) | 18.2507 |
| 2000's | 112 (3.58) | 29.6817 |
| 2010's | 2,007 (64.16) | 24.3611 |
| 2020's | 887 (28.36) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 367 (10.91%) | 5.53% |
| Reviews | 774 (23.01%) | 6.00% |
| Case Studies | 263 (7.82%) | 4.05% |
| Observational | 136 (4.04%) | 0.25% |
| Other | 1,824 (54.22%) | 84.16% |